Jack Jumper Ant Venom免疫療法の長期有効性調査 (JAVELIN)
Jack Jumper ant (JJA) venom allergy is a uniquely Australian medical condition. It is the leading cause of venom allergy and affects up to three per cent of the population. 70 percent of people with JJA allergy will have another reaction on a repeat sting and this sensitivity appears to persist for many years.
Venom immunotherapy (VIT) has been shown to be a safe and effective treatment in the prevention of severe systemic allergic reactions (anaphylaxis) to future stings. It is currently offered to patients as standard care in Tasmania, South Australia and Victoria. However, whilst JJA VIT has been used for many years, there is a lack of evidence on the long-term benefit of the treatment and how it impacts patient quality of life.
This trial will offer patients who have completed a JJA VIT program (between 3 and < 6-years duration) and have been off-treatment for at least 18-months and < 5 years, to have a supervised JJA sting challenge and blood test to assess their JJA venom tolerance level. It will also ask them to complete a set of questionnaires at different timepoints to obtain a history of their exposure and reactions to JJA stings outside of the hospital setting (field stings), and to measure the impact of the completed VIT and knowledge of their sting challenge outcome on their quality of life and their behaviours around auto-injectors.
These measures will be used to explore the long-term effectiveness of JJA VIT and the impact of a sting challenge post VIT on a patient's quality of life.
調査の概要
詳細な説明
This will be a prospective, multicentre, phase 4 clinical trial examining the long-term effectiveness (measured by response to an in-hospital JJA sting challenge, primary outcome) and impact on quality of life of JJA VIT involving 3 Australian tertiary hospital sites offering this treatment - Royal Hobart Hospital, Royal Adelaide Hospital and Monash Medical Centre.
Patients who have completed their JJA VIT (between 3 and <6 years duration) at one of the 3 sites and off-treatment for at least 18 months and < 5 years, will be invited to participate in the trial by their original treating site. A research team member will obtain informed e-consent and a booking for an in-clinic JJA sting challenge will be allocated. For all consented participants, quality of life (QoL), anxiety and depression scores, history of field sting reactions since treatment completion and attitudes toward adrenaline autoinjector carriage/usage will be collected via questionnaire at trial enrolment, sting challenge, 1-month post sting challenge and annually for 3-years. A blood sample will be collected immediately prior to the sting challenge at the in-clinic appointment. Participants will also be asked to consent to access retrospective data related to their completed JJA VIT course from their hospital clinical records.
Optional consents will also be sought from each participant for the collection of an extra tube of blood with the serum biobanked for future analysis, and the inclusion of their data in the National Allergy BioRepository (ALBI).
研究の種類
入学 (推定)
段階
- フェーズ 4
連絡先と場所
研究連絡先
- 名前:National Allergy Centre of Excellence
- 電話番号:61 3 99366752
- メール:nace@mcri.edu.au
研究場所
-
-
South Australia
-
Adelaide、South Australia、オーストラリア、5000
- 募集
- Royal Adelaide Hospital
-
コンタクト:
- National Allergy Centre of Excellence
- 電話番号:61 3 99366752
- メール:nace@mcri.edu.au
-
主任研究者:
- Carlo Yuson, MD FRACP
-
-
Tasmania
-
Hobart、Tasmania、オーストラリア、7000
- 募集
- Royal Hobart Hospital
-
コンタクト:
- National Allergy Centre of Excellence
- 電話番号:61 3 99366752
- メール:nace@mcri.edu.au
-
主任研究者:
- Troy Wanandy, PhD
-
-
Victoria
-
Clayton、Victoria、オーストラリア、3168
- 募集
- Monash Medical Centre
-
コンタクト:
- National Allergy Centre of Excellence
- 電話番号:61 3 99366752
- メール:nace@mcri.edu.au
-
主任研究者:
- Kymble Spriggs, MBBS MPH FRACP FRCP FAAAAI
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Eligibility criteria
- Any adult (≥ 18 years) who has completed a JJA VIT program at one of the three participating sites.
Inclusion Criteria:
- Completed a continuous program of JJA VIT of between 3 and < 6 years duration.
- Have ceased JJA VIT for ≥ 18 months but < 5 years.
- Have the ability to provide informed consent.
Exclusion Criteria:
- Any person < 18 years.
- Any adult (≥ 18 years) who has not completed a continuous JJA VIT program of duration between 3 and < 6 years.
- Any adult (≥ 18 years) who has completed a continuous JJA VIT program of duration between 3 and < 6 years but ceased JJA VIT < 18 months or > 5 years ago.
- Any person who has a medical condition, that in the opinion of the investigator, may place them at increased risk if they were to have a sting challenge.
- Unable to understand study requirements and provide informed consent.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:ジャックジャンパーアリ毒液免疫療法治療を完了した参加者
|
Jack Jumper Ant Venom Immunotherapy involves injections, under the skin, of gradually increasing doses of insect venom. The treatment is usually between 3-<6 years duration. Participants will have completed this treatment at least 18 months prior to their enrolment in this trial. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Presence of a systemic reaction to JJA live ant sting challenge
時間枠:Periprocedural
|
This will be assessed by the clinician and recorded as YES or NO. |
Periprocedural
|
|
Severity of a clinically assessed systemic reaction measured by The Brown Grading Criteria
時間枠:Periprocedural
|
The Brown Grading Criteria measures the severity of anaphylactic reactions by categorizing symptoms based on body systems affected and physiological impact. The tool uses a 3-point grading system: Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe. Higher scores indicate more severe anaphylactic reactions. |
Periprocedural
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in presence of a systemic reaction to a field sting following cessation of Jack Jumper Ant Venom Immunotherapy as reported by the patient on a trial-specific questionnaire
時間枠:At enrolment, 1-month post procedure and annually for 3-years
|
Trial specific questionnaire to be completed by the patient which captures information about any Jack Jumper Ant stings that the patient may have had since completion of Venom Immunotherapy Treatment and whether or not they experienced any type of reaction. If no sting was experienced only one question is required to be answered. If sting/s was experienced ten questions are asked including timing, symptoms, location, treatment and environment. |
At enrolment, 1-month post procedure and annually for 3-years
|
|
Change in severity of a systemic reaction to a field sting following cessation of Jack Jumper Ant Venom Immunotherapy as measured by The Brown Grading Criteria
時間枠:At enrolment, 1-month post procedure and annually for 3-years
|
The Brown Grading Criteria measures the severity of anaphylactic reactions by categorizing symptoms based on body systems affected and physiological impact. The tool uses a 3-point grading system: Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe. Higher scores indicate more severe anaphylactic reactions. |
At enrolment, 1-month post procedure and annually for 3-years
|
|
Change in attitude towards adrenaline auto-injectors as measured by the Adrenaline Auto-injector Questionnaire
時間枠:At enrolment, 1-month post procedure and annually for 3-years
|
The Adrenaline Auto-injector Questionnaire measures patient attitudes and behaviors related to adrenaline auto-injectors as a 4 question survey. Current possession of an adrenaline auto-injector (yes/no), decision-making process regarding auto-injector maintenance (doctor advice, personal decision, or other influence), carrying/storage behaviors (ranging from constant carriage to unknown location), overall attitude assessment using a 7-point scale regarding the advantages and disadvantages of carrying an auto-injector where the minimum score is 1 and the maximum score is 7. A lower score indicates a better outcome. |
At enrolment, 1-month post procedure and annually for 3-years
|
|
Change in quality of life as measured by the Vespid Quality of Life Questionnaire
時間枠:At enrolment, 1-month post procedure and annually for 3-years
|
An adapted insect allergy specific health-related quality of life questionnaire. 14 questions with 7 response options giving a score of 1-7, with lower scores representing a higher quality of life. |
At enrolment, 1-month post procedure and annually for 3-years
|
|
Change in quality of life measured using the Hospital Anxiety and Depression Scale
時間枠:At enrolment, 1-month post procedure and annually for 3-years
|
Developed to assess depression and anxiety. Each response ranges from 0 to 3, the 14 responses are added to yield a total score between 0 and 42. Higher scores indicate higher severity of anxiety and depression. |
At enrolment, 1-month post procedure and annually for 3-years
|
協力者と研究者
捜査官
- 主任研究者:Adriana Le, MBBS FRACP、Royal Hobart Hospital
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
After the data has been cleaned and database has been locked, the de-identified data and if consented, personal identifying information, will be shared to National Allergy Centre of Excellence (NACE) Allergy BioRepository via a safe and secure mechanism, for storage and use in future allergy research.
IPD 共有時間枠
At 6 months post the commencement of JAVELIN, de-identified data, encrypted with NACE unique identifier codes and secure linkage key tokens, will be transferred to the ALBI platform, for storage, integration and sharing for future HREC-approved allergy research purposes. Data once in ALBI remains indefinitely.
IPD 共有アクセス基準
ALBI will only provide researchers with non-identifiable information following the Scientific Access Framework. Researchers need to apply for access to ALBI data. Once approved, data will be made available to the researchers by logging in through a secure research platform. Researchers will not have access to the entire ALBI system as they will be provided extracts from ALBI of non-identifiable information related to their specific request and approval. Information will only be shared with ethically approved future allergy research studies.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- ANALYTIC_CODE
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。